Recent News

• 06.13.2025 - 144 - Report of proposed sale of securities
• 06.10.2025 - Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
• 05.28.2025 - 8-K - Current report
• 05.28.2025 - Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
• 05.20.2025 - 8-K - Current report
• 05.13.2025 - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
• 05.12.2025 - Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
• 05.09.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 05.02.2025 - 8-K - Current report
• 04.23.2025 - Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference

Recent Filings

• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 8-K Current report
• 05.20.2025 - EX-99.1 EX-99.1
• 05.20.2025 - 8-K Current report
• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.02.2025 - 8-K Current report
• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material